Table 1.
Breakdown of study cohort
| Non‐small cell lung cancer† | 148 |
| SCLC | 39 |
| Suspected extrathoracic cancer | 45 |
| Lymphoma | 12 |
| Genito‐urinary (renal, prostate, endometrial) cancer | 7 |
| Breast cancer | 6 |
| Carcinoma of unknown primary (non‐lung) | 6 |
| Colorectal cancer | 3 |
| Malignant mesothelioma | 1 |
| Laryngeal cancer | 1 |
| True negative | 7 |
| False negative | 1 |
| True negative | 43 |
| Surgical resection – nodes clear | 1 |
| Negative mediastinoscopy | 19 |
| PET negative nodes with low SUV | 5 |
| Clinical and radiological stability over 12 month period on CT | 18 |
| False negative | 9 |
| Positive mediastinoscopy | 1 |
| Repeat positive EBUS‐TBNA | 1 |
| Positive EUS‐FNA | 1 |
| Positive CT‐guided lung biopsy with enlarged nodes on CT | 3 |
| Positive bone biopsy with enlarged nodes on CT | 2 |
| PET scan with nodes with high SUV | 1 |
| Total | 284 (200 suspected NSCLC) |
†
Included 80 adenocarcinoma, 47 squamous, 15 undifferentiated, 4 large cell, and 2 neuroendocrine cases.
CT, computed tomography; EBUS‐TNA, endobronchial ultrasound‐guided transbronchial needle aspiration; EUS‐FNA, endoscopic ultrasound‐guided‐fine needle aspiration; PET, positron emission tomography; SCLC, small cell lung cancer; SUV, standard uptake value.